Mark J. Foley - 31 Dec 2023 Form 4 Insider Report for Revance Therapeutics, Inc.

Role
CEO, Director
Signature
/s/ Dwight Moxie, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
31 Dec 2023
Net transactions value
+$1,972
Form type
4
Filing time
03 Jan 2024, 16:47:30 UTC
Previous filing
15 Aug 2023
Next filing
02 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVNC Common Stock Award $1,972 +264 +0.03% $7.47 914,718 31 Dec 2023 Direct F1
holding RVNC Common Stock 110,913 31 Dec 2023 See footnote F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were acquired by Mr. Foley under the Issuer's 2014 Employee Stock Purchase Plan on December 31, 2023 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
F2 These shares are held by the Mark and Dana Foley, Trustees, Foley Family Trust U/A DTD 4/10/2002.